Physicians' Academy for Cardiovascular Education

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019, Athens, Greece - Prof. Subodh Verma - Toronto, ON, Canada

Growing importance of lowering remnants, also in light of the obesity epidemic

3' education - June 3, 2019 - Børge Nordestgaard

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities

3' education - June 3, 2019 - John Chapman, PhD

ARNI as first-line therapy in de novo HFrEF patients after ADHF event

3' education - June 3, 2019

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation

3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD

Genetic variants and elevated risk of CAD

3' education - May 28, 2019 - Heribert Schunkert, MD - Munich, Germany

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - May 22, 2019 - Mark Cooper, MD

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 in Melbourne, Australia - Prof. David Cherney - Toronto, ON, Canada

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia

Detection of AF with wearable technology to prevent stroke

3' education - Apr. 8, 2019

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019

No difference in survival with immediate vs. delayed coronary angiography after cardiac arrest in NSTEMI patients

3' education - Apr. 8, 2019 - Jorrit Lemkes

Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction

3' education - Apr. 8, 2019 - Dr. Eri Kato, Kyoto, Japan

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019

No reduction of recurrent stroke with DOAC after embolic stroke of undetermined source

Literature - June 12, 2019 - Diener H-C, et al. - N Engl J Med 2019

Dabigatran therapy did not result in a reduction of recurrent strokes compared to aspirin use after embolic stroke of undetermined source, whereas nonmajor bleeding was higher with dabigatran.

Elevated Lp(a) levels and apo(a) production in response to statins

Literature - June 12, 2019 - Tsimikas S et al. - Eur Heart J 2019

A meta-analysis showed significantly elevated Lp(a) levels with statin therapy and a cell culture study demonstrated increased apo(a) production after statin treatment, which possibly contributes to the residual CV risk in subjects on statins.

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019, Athens, Greece - Prof. Subodh Verma - Toronto, ON, Canada
Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.

Subodh Verma gives a presentation focusing on various proposed mechanisms through which SGLT2 inhibition can result in a reduction of CV events and HF outcomes.

Oral GLP-1RA non-inferior to placebo in reducing major adverse cardiac events in T2DM with high CV risk

News - June 12, 2019

ADA 2019 Oral formulation of GLP-1RA semaglutide was not inferior to placebo with regard to major adverse cardiac events in T2DM patients with high CV risk.

Comparable CV safety for DPP-4 inhibitor and sulfonylurea in T2DM patients with CVD or high CV risk

News - June 11, 2019

ADA 2019 Results of the CAROLINA trial showed similar CV effects of the DPP-4 inhibitor linagliptin vs. the sulfonylurea glimepiride in T2DM patients with CVD or high CV risk.

SGLT2 inhibitor slows progression of kidney disease and renal death in T2DM patients

News - June 11, 2019

ADA 2019 In a subanalysis of the DECLARE-TIMI 58 trial, patients with T2DM showed reduced progression of kidney disease and fewer renal events when treated with dapagliflozin vs placebo.

GLP-1 receptor agonist lowers MACE in broad range of persons with T2DM

News - June 11, 2019

ADA 2019 The REWIND trial, which included a majority of participants without established CVD, showed that dulaglutide treatment resulted in 12% reduction in MACE, irrespective of history of CVD.

High residual inflammatory risk associated with adverse clinical outcomes in patients undergoing PCI with low LDL-c

Literature - June 7, 2019 - Guedeney P et al. - JACC 2019
A single-center prospective PCI-registry showed an independent association of high residual inflammatory risk and adverse clinical outcomes in patients undergoing PCI with LDL-c ≤70 mg/dL at baseline.

A single-center prospective PCI-registry showed an independent association of high residual inflammatory risk and adverse clinical outcomes in patients undergoing PCI with LDL-c ≤70 mg/dL at baseline.

Almost 1 in 10 of young adults with MI has clinically defined FH

Literature - June 6, 2019 - Singh A et al., - J Am Coll Cardiol. 2019

9% Of adults who experience MI before 50 years of age, have probable or definite FH. Statin therapy is often suboptimal and so are LDL-c levels at 1 year post-MI.

Growing importance of lowering remnants, also in light of the obesity epidemic

EAS 2019 - Maastricht, The Netherlands

3' education - June 3, 2019 - Børge Nordestgaard
Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

EAS 2019 Professor Nordestgaard notes that the importance of remnant cholesterol is increasingly recognized, as it is causally related to risk of ischemic stroke, myocardial infarction and all-cause mortality.

Uninterrupted treatment with NOAC as alternative to VKA for ablation of AF

Literature - June 5, 2019 - Hohnloser SH et al. - Eur Heart J 2019

The exploratory ELIMINATE-AF study demonstrated that uninterrupted treatment with edoxaban represents an alternative to continuous VKA in patients undergoing catheter ablation of AF.

Debate on Lp(a) – treating high levels or not?

News - May 29, 2019
By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk.

EAS 2019 By debating on whether high Lp(a) levels should be treated or not, Brian Ference and Sotirios Tsimikas critically reviewed the available evidence on the link between Lp(a) and CV risk. With poll